Analyst Reco. Incyte Corporation

Equities

INCY

US45337C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
51.74 ^USD	+0.17%		-1.86%	-17.60%

Apr. 24	Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	MT
Apr. 23	Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	Apr. 24	MT
BMO Capital Adjusts Price Target on Incyte to $56 From $64	Apr. 19	MT
Jefferies Initiates Incyte With Buy Rating, Price Target is $81	Feb. 23	MT
BMO Capital Adjusts Price Target on Incyte to $64 From $58, Keeps Market Perform Rating	Feb. 14	MT
Citigroup Adjusts Price Target on Incyte to $81 From $82, Keeps Buy Rating	Feb. 14	MT
JMP Securities Downgrades Incyte to Market Perform From Market Outperform	Feb. 14	MT
Truist Securities Adjusts Price Target on Incyte to $84 From $91, Maintains Buy Rating	Feb. 14	MT
Stifel Adjusts Price Target on Incyte to $68 From $67, Maintains Hold Rating	Feb. 14	MT
The market faces a choice	Feb. 14
RBC Lifts PT on Incyte to $65 From $63 on Model Updates Reflecting Monjuvi Integration, Slightly Improved Jakafi/Opzelura Sales Expectations; Sector Perform Kept	Feb. 14	MT
ANALYST RECOMMENDATIONS : Biogen, Gsk, Hp Inc, Palantir, Walt Disney...	Feb. 14
Mizuho Adjusts Incyte's Price Target to $77 From $82, Keeps Neutral Rating	Dec. 14	MT
Leerink Partners Upgrades Incyte to Outperform From Market Perform, Raises Price Target to $78 From $63	Dec. 13	MT
Guggenheim Upgrades Incyte to Buy From Neutral, Price Target is $86	Dec. 04	MT
Goldman Sachs Downgrades Incyte to Neutral From Buy, Cuts Price Target to $65 From $98	Nov. 21	MT
Goldman Sachs Adjusts Price Target on Incyte to $98 From $114, Keeps Buy Rating	Nov. 02	MT
Morgan Stanley Cuts Incyte Price Target to $64 From $74, Maintains Equal Weight Rating	Nov. 01	MT
RBC Cuts Price Target on Incyte to $63 From $74, Notes Weaker-Than-Expected Q3 Sales, Keeps Sector Perform Rating	Nov. 01	MT
ANALYST RECOMMENDATIONS : Best Buy, Easyjet, Fortinet, Tesla, Netflix...	23-10-19
ANALYST RECOMMENDATIONS : Biogen, Glencore, Home Depot, Meta Platforms, On Semi...	23-10-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am EDT